- Inbunden (Hardback)
- Antal sidor
- 1st ed. 2016
- Jann, Michael (ed.), Cohen, Lawrence (ed.), Penzak, Scott R. (ed.)
- 47 schwarz-weiße Tabellen 20 schwarz-weiße und 5 farbige Abbildungen Bibliographie
- 5 Tables, color; 47 Tables, black and white; 50 Illustrations, color; 50 Illustrations, black and wh
- Antal komponenter
- 1 Hardback
Du kanske gillar
Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents
Fri frakt inom Sverige för privatpersoner.
Skickas inom 10-15 vardagar1669
Passar bra ihop
De som köpt den här boken har ofta också köpt Handbook of Essential Pharmacokinetics, Pharmac... av Younggil Kwon (inbunden).Köp båda 2 för 4748 kr
Fler böcker av författarna
Bloggat om Applied Clinical Pharmacokinetics and Pha...
Michael W. Jann, Pharm.D., FCP, FCCP is Professor and Chair for the Department of Pharmacotherapy at the University of North Texas System College of Pharmacy (UNTSCP) located at the UNT Health Sciences Center (UNTHSC). Professor Jann received his Doctor of Pharmacy degree from the University of Southern California and post-doctoral training in mental health pharmacy practice at the University of Tennessee Memphis College of Pharmacy. He has published over 230 peer-review articles, abstracts, and book chapters and served as a primary investigator for numerous clinical trials in psychopharmacology. Professor Jann serves on the editorial boards of six peer-review scientific journals including CNS Drugs, Molecular Diagnostics and Therapeutics, The Scientific World Journal - Pharmacology Section, The Consultant Pharmacist, Journal of Clinical Pharmacology, and Journal of Pharmacy Practice. Scott R. Penzak, Pharm.D., FCP, is Professor and Vice Chair for the Department of Pharmacotherapy at the University of North Texas System College of Pharmacy (UNTSCP) located at the UNT Health Sciences Center (UNTHSC). Professor Penzak received his Doctor of Pharmacy degree from Wayne State University and completed his post-doctoral training in infectious diseases at the University of Arkansas for Medical Science (UAMS). Prior to UNTSCP, he was the Director of the Clinical Pharmacokinetics Laboratory at the NIH. He has published over 150 peer-review articles, abstracts, and book chapters, and served as a principal investigator on numerous pharmacokinetic and pharmacogeneticstudies. Professor Penzak serves on the editorial boards of three peer-review scientific journals including Journal of Clinical Pharmacology, Pharmacotherapy, and the International Journal of Pharmacokinetics. Lawrence J. Cohen, PharmD, BCPP, FASHP, FCCP, FCP, FNAP is currently Professor of Pharmacotherapy at the University of North Texas System College of Pharmacy. Examples of Professor Cohen's previous service include, Global Director of CNS Research for Kendle International, Director of the Office of Clinical Trials for University of Cincinnati, and Director of Pharmaceutical Services for the Oklahoma Department of Mental Health and Substance Abuse Services. Professor Cohen received his Doctor of Pharmacy degree and post-doctoral training in psychiatric pharmacy from University of Southern California School of Pharmacy. Professor Cohen has been a Board Certified Psychiatry Pharmacist since the specialty was recognized. His relevant service on Editorial Boards include Current Psychiatry, Innovations in Clinical Neuroscience, Primary Care Companion of the Journal of Clinical Psychiatry, Drug Benefit Trends, Journal of the American Medical Directors Association, CNS News and Pharmacy Practice News.
Section 1. General Pharmacokinetic and Pharmacodynamic Principles of Psychopharmacological Agents.- 1. Pharmacokinetic Properties.- 2. Pharmacodynamic Properties.- 3. PET Scan and Other Biomarkers.- 4. Population Pharmacokinetics.- 5. Drug Transporters (esp. Blood Brain Barrier).- 6. Pharmacogenomics.- Section 2. Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Drug Classes.- 7. Antipsychotics - oral typical agents, oral atypical agents, and long-acting injectable (LAI) antipsychotics.- 8. Mood Stabilizers.- 9. Antidepressants - tricyclics, selective serotonergic reuptake inhibitors, serotonergic noradrenergic reuptake inhibitors, monoamine oxidase inhibitors, and other antidepressants.- 10. Benzodiazepines and Other Sedative Hypnotics/Anxiolytics.- 11. Opioid Analgesics.- 12. Stimulants and Other Non-Stimulants for ADHD.- 13. Cholinesterase Inhibitors and Other Antidementa Agents.- 14. Anti-Addiction Agents.- 15. Anesthetics.- Section 3. Clinically Significant Drug Interactions With Psychopharmacological Agents.- 16. Antipsychotics.- 17. Mood Stabilizers.- 18. Antidepressants.- 19. Benzodiazepines and Other Sedative Hypnotics/Anxiolytics.- 20. Opioid Analgesics.- 21. Stimulants and Other Non-Stimulants for ADHD.- 22. Cholinesterase Inhibitors and Other Antidementa Agents.- 23. Anti-Addiction Agents.- 24. Anesthetics.